![]() ![]() ![]() It included an early test of how well the vaccine was tolerated in different age groups. The trial was designed to enroll as many as 4,500 children to test the safety and efficacy of the companies' messenger RNA vaccine. ![]() As a result, the trial is being modified to include a third dose of vaccine for participants in this age group. Children in the 2- to 5-year age group didn't produce as strong of an antibody response to the vaccine as older and younger children did. On Friday, Pfizer and BioNTech announced that their latest vaccine trial was showing some odd results in children within a specific age range.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |